Climb Bio, Inc.

CLYM

Healthcare|Biotechnology|US

$10.29

+1.42 (+16.01%)

DCF Value

$0.49

Tangible Book / Share

$2.85

Cash / Share

$2.57

About

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Stock Price

+427.7%(1Y)

-5.2%

-26.5%

-9.5%

YTD

+157.3%

+471.7%

+31.4%

Pipeline Summary

6 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 5Completed: 1

Active Trials (5)

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

NCT07043946Immune Thrombocytopenia (ITP)

Phase 1Phase 2Recruiting

Enrollment: 24 participants

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043Systemic Lupus Erythematosus

Phase 1Recruiting

Enrollment: 30 participants

A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07564596Systemic Lupus Erthematosus

Phase 1Phase 2Recruiting

Enrollment: 30 participants

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT07096843Primary Membranous Nephropathy

Phase 2Recruiting

Enrollment: 45 participants

A Phase 1 Study of CLYM116 in Normal Healthy Volunteers

NCT07248865Healthy Volunteers

Phase 1Recruiting

Enrollment: 48 participants

Key Facts

Market Cap$591.0M

Employees28

CEOAoife Brennan BCh MMSc

IPO DateAug 10, 2021

Beta0.07

52-Week Range$1.635 – $18.33

Avg Volume1,338,322

ExchangeNASDAQ

Websiteclimbbio.com